Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and safety of GSK Biologicals' candidate tuberculosis (TB) vaccine (692342) when administered to healthy adults aged 21 to 40 years.

Next Previous
Trial Profile

Immunogenicity and safety of GSK Biologicals' candidate tuberculosis (TB) vaccine (692342) when administered to healthy adults aged 21 to 40 years.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 692342 (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 15 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 15 Jul 2008 The expected completion date for this trial has been extended from Nov 2008 to Dec 2008 as reported by ClinicalTrials.gov.
  • 15 Jul 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top